Boston Scientific Corp: (NYSE: BSX)
$9.54
-0.10 (-1.04%)
Volume 12,122,822
Jun 18 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 9.51 - 9.68 |
| 52wk Low - High | 4.79 - 9.75 |
| Previous Close | 9.64 |
| Avg. Volume | 16,878,086 |
| Industry | MED PRODUCTS |
| Market Cap | 13.01 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.19 |
| P/E (F1) | 14.39 |
| Current Year Est. | 0.67 |
| Quarterly Earnings ESP |
6.25% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
178 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | 14.39 |
| PEG Ratio | 1.99 |
| Current Year Est. | 0.67 |
| Current Quarter Estimate | 0.16 |
| Most Accurate Estimate | 0.17 |
| Earnings ESP |
6.25% |
| Next Earnings Report Date | 07-25-2013 |
| EPS Last Year | 0.67 |
| Expected Earnings Growth | 7.24% |
Company Description
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The company's products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.16 | 0.16 | 0.67 | 0.73 |
| Number of Estimates | 11 | 11 | 11 | 11 |
| Low Estimate | 0.16 | 0.15 | 0.65 | 0.69 |
| High Estimate | 0.17 | 0.17 | 0.68 | NA |
| Year Ago EPS | 0.17 | 0.16 | 0.66 | 0.67 |
| EPS Growth | -5.35% | 0.00% | 1.52% | 8.96% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| BOSTON SCIENTIF | BSX | 9.64 | |
|
| HAEMONETICS CP | HAE | 42.30 | |
|
| ATRICURE INC | ATRC | 9.19 | |
|
| BAXANO SURGICAL | BAXS | 2.30 | |
|
| CARDICA INC | CRDC | 1.15 | |
|
| ESSILOR INTL SA | ESLOY | 56.04 | |
|
| INVIVO THERAPT | NVIV | 4.00 | |
|
| PURE BIOSCIENCE | PURE | 0.34 | |
|
| SHANDONG WEIGAO | SHWGF | 1.29 | |
|
| ABAXIS INC | ABAX | 46.65 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
BSX Commences U.S. INTREPID Trial
Jun 18, 2013
St. Jude Expands Neuro Offerings
Jun 10, 2013
STJ Begins U.S. Trial for EnligHTN
Jun 05, 2013
BSX Funding for Women's Health
Jun 04, 2013
Medtronic Endovascular Biz in Focus
May 31, 2013
BSX Grows Neuromodulation Portfolio
May 28, 2013
St. Jude Begins EnligHTNment Study
May 24, 2013
BSX Entangled in Patent Issues
May 22, 2013
Financials
| EPS TTM | 0.67 |
| Sales | 7,249 |
| Net Income | -4,423 |
| Price/Earnings | 14.39 |
| Price/Book | 2.01 |
| Price/Cash Flow | 2.17 |
| Price/Sales | 1.82 |
News
Market Maker Surveillance Report. DVAX, BSX, MNKD, ALU, AGNC, NEWL, Highest Net Sell Volume and Negative Price Friction For Tuesday, June 18th 2013 - M2
Jun 19, 2013
Boston Scientific Vercise DBS System Demonstrates Improveed Motor Function in Parkinson`s Patients - Benzinga
Jun 18, 2013
Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman - Prweb
Jun 18, 2013
Zimmer has the Best Relative Performance in the Health Care Equipment Industry (ZMH, DXCM, IDXX, BDX, BSX) - Financial News Network Online - News Corner
Jun 18, 2013
Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise(TM) DBS System In Treatment Of Parkinson's Disease - Pr Newswire
Jun 17, 2013
Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise(TM) DBS System In Treatment Of Parkinson's Disease - Pr Newswire Europe
Jun 17, 2013
Boston Scientific Looks to Continue to Trade Above its Annual-High Share Price Today - Financial News Netwfork Online - 52-Week High-Lows
Jun 17, 2013
Boston Scientific Vercise(TM) DBS System demonstrates Improvement In Motor Function For Patients With Parkinson's Disease - Pr Newswire
Jun 17, 2013
Broker Recommendations
| Current ABR | 2.47 |
| ABR (Last Week) | 2.47 |
| # of recs in ABR | 19 |
| Average Target Price | 8.23 |
| Industry Rank by ABR | 178 out of 265 |
| Rank in Industry | 6 out of 72 |
